CANCER GENOMICS CONSORTIUM (EIN 273232063) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2010

Legal Domicile

Phone

6087722963

Tax Period

2025-01-01 to 2025-12-31

CANCER GENOMICS CONSORTIUM, founded in 2010, is a small nonprofit in the Medical Research sector that reported $512K in total revenue in fiscal year 2025. Revenue grew 17% year-over-year, indicating healthy expansion.

Mission

THE CANCER GENOMICS CONSORTIUM (CGC) IS COMMITTED TO PROVIDING HIGH QUALITY EDUCATION AND PROMOTING BEST LABORATORY PRACTICES IN CLINICAL CANCER GENOMICS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $15,098

Program Service Revenue $477,467

Investment Income $19,253

Other Revenue $0

TOTAL REVENUE $511,818

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $11,873

Program Expenses $433,276

Other Expenses $498,411

TOTAL EXPENSES $498,411

Year-over-Year Comparison

	2025	2024	Change
Revenue	$511,818	$436,621	+0.2%
Expenses	$498,411	$469,290	+0.1%
Net Income	$13,407	$-32,669	-1.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

127

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
N/A	BOARD MEMBER	0.50	Director	$0	$0	$0
N/A	BOARD MEMBER	0.50	Director	$0	$0	$0
N/A	PRESIDENT -	1.00	Officer Director	$0	$0	$0
N/A	TREASURER	1.00	Officer Director	$0	$0	$0
ANGELA LAGER PHD FACMG	SECRETARY	1.00	Officer Director	$0	$0	$0
N/A	PRESIDENT	1.00	Officer Director	$0	$0	$0
N/A	PAST - PRESI	1.00	Officer Director	$0	$0	$0
N/A	BOARD MEMBER	0.50	Director	$0	$0	$0
MEGAN FORREST PHD	JUNIOR BOARD	0.50	Director	$0	$0	$0
WESLEY GOAR PHD	JUNIOR BOARD	0.50	Director	$0	$0	$0
N/A	BOARD MEMBER	0.50	Director	$0	$0	$0
N/A	BOARD MEMBER	0.50	Director	$0	$0	$0
N/A	BOARD MEMBER	0.50	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$511,818	$498,411	$571,996	$13,407
2024	No data	No data	No data	No data
2023	$441,040	$446,547	$580,120	$-5,507
2022	$471,897	$380,318	$534,562	$91,579
2021	$289,070	$180,642	$470,210	$108,428
2020	$155,534	$145,205	$361,835	$10,329
2019	$327,435	$308,911	$301,707	$18,524
2019	$327,435	$308,911	$301,707	$18,524
2018	$288,811	$258,884	$283,183	$29,927

CANCER GENOMICS CONSORTIUM